Claire S Faulkner1,2, Collin M White2,3, Wuttiporn Manatsathit2, Bernadette Lamb2, Vatsalya Vatsalya3,4,5,6, Craig J McClain3,4,5,6,7, Loretta L Jophlin2,3,4,6. 1. Department of Medicine, University of Arizona, College of Medicine, Phoenix, Arizona, USA. 2. Department of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, Nebraska, USA. 3. Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, Kentucky, USA. 4. University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky, USA. 5. Robley Rex VA Medical Center, Louisville, Kentucky, USA. 6. Hepatobiology and Toxicology Program, University of Louisville, Louisville, Kentucky, USA. 7. Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA.
Abstract
BACKGROUND: Excessive alcohol use is a leading etiology of liver disease and indication for liver transplantation. Accurate measurement of alcohol use remains a challenge in the management of patients in the pre-, peri-, and post-liver transplant settings. Blood 16:0-18:1 phosphatidylethanol (PEth) concentration is a sensitive and specific biomarker of binge and moderate, chronic alcohol use. As PEth has the longest detection window of available blood-based direct alcohol biomarkers for moderate to heavy drinking, it shows promise as an indicator of patterns and chronicity of drinking. However, the utility of PEth in clinical liver transplantation is understudied. This study examines the association of PEth results with liver transplantation waitlist-focused patient outcomes. METHODS: Retrospective data for all patients tested for PEth for a one-year period at a tertiary care medical center with an active liver transplantation program were abstracted. Indications for PEth testing, liver transplantation waitlist-related outcomes (e.g., listing and delisting) following testing and associations of PEth results with other parameters were analyzed. RESULTS: Over a one-year period, 153 PEth tests were performed on 109 individuals. The most frequent indications for PEth testing were as an objective indicator of alcohol use patterns (86.3%) and to assess alcohol as a putative etiology of liver injury (13.7%). Of the 109 patients, 56 were medically appropriate for liver transplantation. Medically acceptable candidates with unfavorable transplantation waitlist-related outcomes (delisting, deferment of transplant evaluation, deferment of listing until completion of recommended alcohol rehabilitation, and being deemed not a transplant candidate) were at least 3.41 times more likely to have a positive PEth test than those with favorable transplantation waitlist-related outcomes (odds ratio 3.41, confidence interval 3.41 to ∞, p = 0.001). CONCLUSION: This single-center study reporting a comprehensive account of PEth utilization at a liver transplant center demonstrates that liver transplantation waitlist-related outcomes are associated with PEth test results. Patients with positive PEth tests were more likely to have unfavorable transplant waitlist-related outcomes. PEth testing has not been validated as a predictor of relapse to drinking in post-transplant patients and because its utility in the pre-transplant setting is unclear its use could lead to disparities in the selection of patients for liver transplantation.
BACKGROUND: Excessive alcohol use is a leading etiology of liver disease and indication for liver transplantation. Accurate measurement of alcohol use remains a challenge in the management of patients in the pre-, peri-, and post-liver transplant settings. Blood 16:0-18:1 phosphatidylethanol (PEth) concentration is a sensitive and specific biomarker of binge and moderate, chronic alcohol use. As PEth has the longest detection window of available blood-based direct alcohol biomarkers for moderate to heavy drinking, it shows promise as an indicator of patterns and chronicity of drinking. However, the utility of PEth in clinical liver transplantation is understudied. This study examines the association of PEth results with liver transplantation waitlist-focused patient outcomes. METHODS: Retrospective data for all patients tested for PEth for a one-year period at a tertiary care medical center with an active liver transplantation program were abstracted. Indications for PEth testing, liver transplantation waitlist-related outcomes (e.g., listing and delisting) following testing and associations of PEth results with other parameters were analyzed. RESULTS: Over a one-year period, 153 PEth tests were performed on 109 individuals. The most frequent indications for PEth testing were as an objective indicator of alcohol use patterns (86.3%) and to assess alcohol as a putative etiology of liver injury (13.7%). Of the 109 patients, 56 were medically appropriate for liver transplantation. Medically acceptable candidates with unfavorable transplantation waitlist-related outcomes (delisting, deferment of transplant evaluation, deferment of listing until completion of recommended alcohol rehabilitation, and being deemed not a transplant candidate) were at least 3.41 times more likely to have a positive PEth test than those with favorable transplantation waitlist-related outcomes (odds ratio 3.41, confidence interval 3.41 to ∞, p = 0.001). CONCLUSION: This single-center study reporting a comprehensive account of PEth utilization at a liver transplant center demonstrates that liver transplantation waitlist-related outcomes are associated with PEth test results. Patients with positive PEth tests were more likely to have unfavorable transplant waitlist-related outcomes. PEth testing has not been validated as a predictor of relapse to drinking in post-transplant patients and because its utility in the pre-transplant setting is unclear its use could lead to disparities in the selection of patients for liver transplantation.
Authors: Christie Y Jeon; David C Whitcomb; Adam Slivka; Randall E Brand; Andres Gelrud; Gong Tang; Judah Abberbock; Samer AlKaade; Nalini Guda; C Mel Wilcox; Bimaljit S Sandhu; Dhiraj Yadav Journal: Alcohol Alcohol Date: 2019-12-01 Impact factor: 2.826
Authors: Susanne Hartmann; Steina Aradottir; Marc Graf; Gerhard Wiesbeck; Otto Lesch; Katrin Ramskogler; Manfred Wolfersdorf; Christer Alling; Friedrich Martin Wurst Journal: Addict Biol Date: 2007-03 Impact factor: 4.280
Authors: Alexandra Schröck; Annette Thierauf-Emberger; Stefan Schürch; Wolfgang Weinmann Journal: Int J Legal Med Date: 2016-09-05 Impact factor: 2.686
Authors: Brian P Lee; Eric Vittinghoff; Jennifer L Dodge; Giuseppe Cullaro; Norah A Terrault Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873
Authors: Steina Aradóttir; Stephan Seidl; Friedrich M Wurst; Bo A G Jönsson; Christer Alling Journal: Alcohol Clin Exp Res Date: 2004-11 Impact factor: 3.455